NYSE$SRNE
Sorrento Therapeutics Inc · Q2 2016 earnings
Q2 2016 earnings · · Investor relations
Headline financials
Revenue & EPS history
Sorrento · Revenue · Quarterly
$902K
Q2 2016-23.1%vs Q2 2015
Revenue by segment
Sorrento · $18.4M total across 1 segment · Q1 2022
- ZTlido$18.4M+26.0%100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2016
-0.3%
Avg return
Earnings day
+3.1%
Avg return
5 days after
+6.9%
Avg return
30 days after
38%
13 / 34 earnings
Positive
+41.2%
Q2 2020
Best reaction
-15.6%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2023 | +29.2% | +7.3% | +207.9% | |
| Q2 2023 | +11.6% | -13.9% | +16.7% | |
| Q1 2023 | -4.3% | +2.7% | -15.1% | |
| Q4 2022 | +13.8% | +25.6% | +5.6% | |
| Q3 2022 | -2.8% | +26.2% | -25.5% | |
| Q2 2022 | -4.2% | -29.3% | -21.3% | |
| Q1 2022 | -6.9% | -15.1% | -25.4% | |
| Q4 2021 | -11.1% | +6.7% | -12.4% | |
| Q3 2021 | -4.8% | -7.2% | -28.3% | |
| Q2 2021 | +2.7% | +4.7% | +2.9% | |
| Q1 2021 | +0.1% | +3.4% | +2.9% | |
| Q4 2020 | +0.0% | -14.4% | -25.4% | |
| Q3 2020 | -15.6% | -7.6% | +17.6% | |
| Q2 2020 | +41.2% | +47.6% | -27.7% | |
| Q1 2020 | -6.5% | +34.1% | +22.7% | |
| Q4 2019 | -3.2% | +0.0% | -8.6% | |
| Q3 2019 | -6.0% | -8.4% | +149.7% | |
| Q2 2019 | -6.8% | -6.8% | -2.7% | |
| Q1 2019 | -10.5% | -9.5% | -23.2% | |
| Q4 2017 | +13.2% | +43.6% | +70.8% | |
| Q4 2018 | +13.2% | +43.6% | +70.8% | |
| Q3 2018 | -12.8% | -17.8% | -25.0% | |
| Q2 2018 | +0.9% | -4.7% | -7.5% | |
| Q1 2018 | -7.8% | +4.9% | +19.4% | |
| Q3 2017 | +0.0% | -11.5% | -13.5% | |
| Q2 2017 | -10.3% | -9.0% | -10.3% | |
| Q1 2017 | -10.0% | -16.3% | -51.2% | |
| Q4 2016 | +1.2% | -1.2% | -56.6% | |
| Q3 2016 | +7.3% | +19.1% | -1.8% | |
| Q2 2016 | +0.1% | -4.5% | +1.0% | |
| Q1 2016 | +4.2% | — | — | |
| Q4 2015 | -13.6% | — | — | |
| Q3 2015 | -9.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro